Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | LTA4H | P09960 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | BAX | Q07812 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28451848 | 1.00 | TSHR (0.50) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Hydrochloric Acid SCHEMBL4258270 | 0.96 | TSHR (0.47) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Hydrochloric Acid SCHEMBL28617519 | 0.96 | TSHR (0.47) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Hydrochloric Acid SCHEMBL8695009 | 0.96 | TSHR (0.47) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Arsenic SCHEMBL6243916 | 0.96 | TSHR (0.47) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Phosphine SCHEMBL423880 | 0.96 | TSHR (0.47) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Hydrochloric Acid SCHEMBL1466370 | 0.93 | TSHR (0.44) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Hydrochloric Acid SCHEMBL3277975 | 0.93 | TSHR (0.44) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Phosphoric Acid SCHEMBL29032829 | 0.82 | SRC (0.42) | TSHRLTA4HCA4ALDH1A1KCNA3 | |
| Phosphoric Acid SCHEMBL29169671 | 0.82 | SRC (0.54) | TSHRCA4ALDH1A1CA5ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118652242-B | Aggregation-induced emission type photosensitizer with I-type active oxygen generation capacity and preparation method and application thereof | 内蒙古大学 | 2024-10-18 | — | — | CN | claimed |
| CN-118652242-A | Aggregation-induced emission type photosensitizer with I-type active oxygen generation capacity and preparation method and application thereof | 内蒙古大学 | 2024-09-17 | — | — | CN | claimed |
| CN-107771178-A | Synthesis of heterocyclic compounds | 普莱希科公司 | 2018-03-06 | — | — | CN | claimed |
| CN-102603568-A | Fluorine-containing bis-diphenylacetylene liquid crystal compound and preparation method thereof | UNIV BEIJING SCIENCE & TECH | 2012-07-25 | — | — | CN | claimed |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| EP-4587463-A1 | COMPOSITIONS AND METHODS FOR VIROTHERAPY | Yeda Research and Development Co. Ltd (IL) | 2025-07-23 | — | — | EP | disclosed |
| CN-119432083-A | 3D printed cartilage carving model and manufacturing method thereof | 埃肯有机硅（上海）有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-118652242-B | Aggregation-induced emission type photosensitizer with I-type active oxygen generation capacity and preparation method and application thereof | 内蒙古大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-118652242-A | Aggregation-induced emission type photosensitizer with I-type active oxygen generation capacity and preparation method and application thereof | 内蒙古大学 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024138379-A1 | USE OF COATING SYSTEM COMPRISING ACRYLIC PRE-COAT AND SILICONE TOP-COAT IN A PAPER-BASED FOOD CONTAINER AND THE PAPER-BASED FOOD CONTAINER COATED WITH THE COATING SYSTEM | ELKEM SILICONES SHANGHAI CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024057315-A1 | COMPOSITIONS AND METHODS FOR VIROTHERAPY | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-21 | — | — | WO | disclosed |
| CN-115551867-B | Fused tricyclic compounds, pharmaceutical compositions and uses thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | disclosed |
| EP-1495003-A1 | FREDERICAMYCIN DERIVATIVES | Biofrontera Discovery Gmbh (DE) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087060-A1 | FREDERICAMYCIN DERIVATIVES | BIOFRONTERA DISCOVERY GMBH (DE) | 2003-10-23 | — | — | WO | disclosed |
| CN-1323211-A | New pharmaceutical use of NOS inhibitors | PFIZER PROD INC (US) | 2001-11-21 | — | — | CN | disclosed |
| CN-1277607-A | 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-HT1A, 5-HT1b and 5-HT1D) | BASF AG (DE) | 2000-12-20 | — | — | CN | disclosed |
| CN-1268133-A | 2-Aminopyridines containing fused ring substituents as NOS inhibitors | PFIZER PROD INC (US) | 2000-09-27 | — | — | CN | disclosed |
| CN-1031057-C | Triazolo [4.3-a][1,4] benzodiazepine and thiopheno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepine | HOFFMANN LA ROCHE (CH) | 1996-02-21 | — | — | CN | disclosed |
| CN-1034722-A | Triazole [4,3-a] [1,4] benzodiazepines and thieno-[3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepine | HOFFMANN LA ROCHE (CH) | 1989-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | PSMA1, ACP3, FOLH1 | TSHR 1262/4885LTA4H 2555/4885CA4 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.